藥劑部參考美國 Johns Hopkins 大學研究團隊所建立的 NxP (Nephrotoxic Potential) 專家共識分級清單，本品具「顯著以上腎毒性風險」，被認定具中度至高度腎損傷潛勢，特別是同時合併其他腎毒性藥物、脫水、高齡或既有腎功能異常的患者族群，應更加注意。

#高警訊藥品

黴菌感染
1. Cryptococcal meningitis in patients with HIV
2. Fungal infections: Empiric treatment in febrile neutropenic patients with presumed fungal infection; Systemic infections caused by Aspergillus sp, Candida sp, Cryptococcus sp
3. Visceral leishmaniasis

Antifungal Agent, Parenteral
Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages.

Distribution: Vd 0.1-0.16 L/kg
Half-life elimination: 7 to 10 hours
Terminal half to life: 100 to 153 hours

Hypersensitivity to amphotericin B deoxycholate or any component of the formulation

B; Amphotericin B is recommended for the treatment of serious systemic fungal diseases in pregnant women

Because of the potential for toxicity, breast-feeding is not recommended by the manufacturer

Chills, insomnia, headache, skin rash, hypokalemia, hypomagnesemia, nausea, vomiting, diarrhea, anemia

Usual dosage range: 3 to 6 mg/kg/day

Empiric therapy: 3 mg/kg/dose once daily

1. There are no dosage adjustments provided in the manufacturer's labeling; has been successfully administered to patients with preexisting renal impairment.
2. End-stage renal disease (ESRD) on intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Poorly dialyzed; no dosage adjustment necessary

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Store at 25 degrees C